Results 41 to 50 of about 12,163 (174)

Edoxaban in Asian Patients With Atrial Fibrillation Effectiveness and Safety [PDF]

, 2018
Background It is unclear whether edoxaban shows better risk reduction of ischemic stroke, bleeding, and all-cause mortality than warfarin in Asian patients with nonvalvular atrial fibrillation (AF).
Jung, Jin-Hyung, Lee, So-Ryoung, Oh, Seil, Choi, Eue-Keun, Lip, Gregory YH, Han, Kyung-Do, Lip, Gregory Y H   +6 more
core   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis

Scientific Reports
Portal vein thrombosis (PVT) worsens the long-term prognosis of patients with cirrhosis; however, the optimal treatment remains to be determined. Reports on the efficacy of direct oral anticoagulants are increasing, and further evidence is needed ...
Tomoko Tadokoro, Joji Tani, Takushi Manabe, Kei Takuma, Mai Nakahara, Kyoko Oura, Shima Mimura, Koji Fujita, Takako Nomura, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Masafumi Ono, Tsutomu Masaki   +13 more
doaj   +1 more source

The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation

Атеротромбоз, 2020
Edoxaban is a selective direct factor Xa inhibitor. Edoxaban in a dose of 60 mg per day is an effective and safe option in the prevention of thromboembolic complications in patients with nonvalvular atrial fibrillation, including in combination therapy ...
O. O. Shakhmatova
doaj   +1 more source

Pulmonary Embolism—A Century of Progress

ANZ Journal of Surgery, EarlyView.
Reviews a century of progress in the diagnosis, prevention, and management of pulmonary embolism; from the first successful surgical embolectomy in 1924 to advanced imaging, pharmacological thromboprophylaxis, and treatment. In the 21st century, advances include catheter‐directed thrombolysis or mechanical thrombectomy under decision‐making guidance of
D. A. Watters
wiley   +1 more source

Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution

CPT: Pharmacometrics & Systems Pharmacology, 2023
This study aimed to develop a physiologically‐based pharmacokinetic pharmacodynamic (PBPK/PD) parent‐metabolite model of edoxaban, an oral anticoagulant with a narrow therapeutic index, and to predict pharmacokinetic (PK)/PD profiles and potential drug ...
Ruijuan Xu, Wenyuan Liu, Weihong Ge, Hua He, Qing Jiang   +4 more
doaj   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Factors related to inappropriate edoxaban use

, 2020
What is known and objective The aim of this study was to evaluate the appropriateness and clinical outcomes of edoxaban use, and to determine the role of clinical pharmacists in improving the efficacy and safety of edoxaban use.
이정연
core   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital

Journal of Pharmaceutical Health Care and Sciences, 2020
Background The anticoagulant edoxaban is used clinically at doses of 30–60 mg/day; however, we experienced a patient who had taken an overdose of edoxaban of 750 mg.
Koichiro Adachi, Jumpei Tuchiya, Satoru Beppu, Kei Nishiyama, Makiko Shimizu, Hiroshi Yamazaki   +5 more
doaj   +1 more source